Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus DYLOJECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus DYLOJECT.
ADVIL LIQUI-GELS vs DYLOJECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Category C
Category C
NSAID
NSAID